Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).

Vikas OstwalAnant RamaswamyVikram GotaPrabhat G BhargavaSujay SrinivasBharati ShriyanShraddha JadhavMahesh GoelShraddha PatkarSarika MandavkarDeepali NaughaneAnuprita DaddiChaitali NashikkarNitin ShettySuman Kumar AnkathiShripad D Banavali

Published in: The oncologist (2022)

The SAM combination in HCC patients with predominantly unfavorable baseline disease characteristics showed a marked reduction in sorafenib-related side effects. Studies using sorafenib 600 mg per day in this combination along with sorafenib drug level monitoring can be evaluated in further trials.(Trial ID: CTRI/2018/07/014865).

Keyphrases

clinical trial
study protocol
emergency department
phase ii
drug induced
adverse drug